Pfizer’s vaccine effectiveness against Covid-19 infection drops to 12 percent in 5 to 11-year-olds, suggests a preprint study. Though not peer reviewed, the findings of the study by scientists at the New York State Department of Health confirms that there is at least limited evidence on the effectiveness of the BNT162b2 vaccine for children, particularly those 5-11 years and after the Omicron variant’s emergence. In the Omicron era, the effectiveness of BNT162b2 declined rapidly for children. While vaccination of children against the previous variants was reportedly protective against severe disease and was recommended, the new results highlight the potential need to study alternative vaccine dosing for children.

Source: medrxiv